CRONOS GROUP INC(NASDAQ:CRON) stock Fundamental Analysis

Fundamental Rating

We assign a fundamental rating of 5 out of 10 to CRON. CRON was compared to 198 industry peers in the Pharmaceuticals industry. While CRON has a great health rating, there are worries on its profitability. While showing a medium growth rate, CRON is valued expensive at the moment.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year CRON was profitable.

In the past year CRON had a positive cash flow from operations.

CRON had negative earnings in 4 of the past 5 years.

CRON had negative operating cash flow in 4 of the past 5 years.

1.2 Ratios

CRON has a better Return On Assets (3.52%) than 85.86% of its industry peers.

With an excellent Return On Equity value of 3.86%, CRON belongs to the best of the industry, outperforming 84.85% of the companies in the same industry.

		Industry Rank	Sector Rank
ROA	3.52%
ROE	3.86%
ROIC	N/A

ROA(3y)-5.62%

ROA(5y)-9.8%

ROE(3y)-5.87%

ROE(5y)-10.3%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

With an excellent Profit Margin value of 34.93%, CRON belongs to the best of the industry, outperforming 97.47% of the companies in the same industry.

CRON's Profit Margin has declined in the last couple of years.

CRON has a Gross Margin (21.42%) which is in line with its industry peers.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	34.93%
GM	21.42%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5Y-62.81%

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

CRON does not have a ROIC to compare to the WACC, probably because it is not profitable.

CRON has more shares outstanding than it did 1 year ago.

CRON has more shares outstanding than it did 5 years ago.

CRON has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

2.2 Solvency

CRON has an Altman-Z score of 5.53. This indicates that CRON is financially healthy and has little risk of bankruptcy at the moment.

CRON has a Altman-Z score of 5.53. This is amongst the best in the industry. CRON outperforms 85.35% of its industry peers.

There is no outstanding debt for CRON. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	0
Altman-Z	5.53

ROIC/WACCN/A

WACC8.35%

2.3 Liquidity

CRON has a Current Ratio of 18.84. This indicates that CRON is financially healthy and has no problem in meeting its short term obligations.

CRON's Current ratio of 18.84 is amongst the best of the industry. CRON outperforms 91.41% of its industry peers.

A Quick Ratio of 18.17 indicates that CRON has no problem at all paying its short term obligations.

CRON's Quick ratio of 18.17 is amongst the best of the industry. CRON outperforms 91.41% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	18.84
Quick Ratio	18.17

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

CRON shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 190.91%, which is quite impressive.

Measured over the past years, CRON shows a very negative growth in Earnings Per Share. The EPS has been decreasing by -50.78% on average per year.

The Revenue has grown by 33.82% in the past year. This is a very strong growth!

CRON shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 37.71% yearly.

EPS 1Y (TTM)190.91%

EPS 3YN/A

EPS 5Y-50.78%

EPS Q2Q%320%

Revenue 1Y (TTM)33.82%

Revenue growth 3Y16.47%

Revenue growth 5Y37.71%

Sales Q2Q%26.7%

3.2 Future

The Earnings Per Share is expected to decrease by -21.14% on average over the next years. This is quite bad

CRON is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 1.87% yearly.

EPS Next Y-144.2%

EPS Next 2Y-9.67%

EPS Next 3Y-39.52%

EPS Next 5Y-21.14%

Revenue Next Year18.44%

Revenue Next 2Y12.81%

Revenue Next 3Y7.09%

Revenue Next 5Y1.87%

3.3 Evolution

When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

A Price/Earnings ratio of 18.20 indicates a rather expensive valuation of CRON.

Based on the Price/Earnings ratio, CRON is valued cheaply inside the industry as 83.84% of the companies are valued more expensively.

The average S&P500 Price/Earnings ratio is at 28.87. CRON is valued slightly cheaper when compared to this.

The Forward Price/Earnings Ratio is negative for CRON. No positive earnings are expected for the next year.

		Industry Rank	Sector Rank
PE	18.2
Fwd PE	N/A

4.2 Price Multiples

Based on the Price/Free Cash Flow ratio, CRON is valued a bit cheaper than the industry average as 76.26% of the companies are valued more expensively.

		Industry Rank	Sector Rank
P/FCF	123.3
EV/EBITDA	N/A

4.3 Compensation for Growth

CRON's earnings are expected to decrease with -39.52% in the coming years. This may justify a cheaper valuation.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y-9.67%

EPS Next 3Y-39.52%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

CRON does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

CRONOS GROUP INC

NASDAQ:CRON (4/29/2025, 10:12:56 AM)

1.82

-0.01 (-0.55%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryPharmaceuticals

Earnings (Last)02-27 2025-02-27/bmo

Earnings (Next)05-08 2025-05-08

Inst Owners13.13%

Inst Owner Change-0.95%

Ins Owners5.48%

Ins Owner Change12.54%

Market Cap701.45M

Analysts74.55

Price Target2.66 (46.15%)

Short Float %2.01%

Short Ratio2.55

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)2

Avg EPS beat(2)1006.46%

Min EPS beat(2)296.08%

Max EPS beat(2)1716.84%

EPS beat(4)3

Avg EPS beat(4)340.81%

Min EPS beat(4)-684.31%

Max EPS beat(4)1716.84%

EPS beat(8)5

Avg EPS beat(8)171.4%

EPS beat(12)6

Avg EPS beat(12)82.3%

EPS beat(16)8

Avg EPS beat(16)61.24%

Revenue beat(2)1

Avg Revenue beat(2)-2.63%

Min Revenue beat(2)-14.99%

Max Revenue beat(2)9.73%

Revenue beat(4)3

Avg Revenue beat(4)0.24%

Min Revenue beat(4)-14.99%

Max Revenue beat(4)9.73%

Revenue beat(8)4

Avg Revenue beat(8)-1.68%

Revenue beat(12)5

Avg Revenue beat(12)-4.39%

Revenue beat(16)7

Avg Revenue beat(16)-4.15%

PT rev (1m)4.45%

PT rev (3m)4.49%

EPS NQ rev (1m)N/A

EPS NQ rev (3m)100%

EPS NY rev (1m)-44.43%

EPS NY rev (3m)3.71%

Revenue NQ rev (1m)0%

Revenue NQ rev (3m)-9.17%

Revenue NY rev (1m)2.63%

Revenue NY rev (3m)0.01%

Valuation

		Industry Rank	Sector Rank
PE	18.2
Fwd PE	N/A
P/S	5.96
P/FCF	123.3
P/OCF	37.23
P/B	0.66
P/tB	0.71
EV/EBITDA	N/A

EPS(TTM)0.1

EY5.49%

EPS(NY)-0.04

Fwd EYN/A

FCF(TTM)0.01

FCFY0.81%

OCF(TTM)0.05

OCFY2.69%

SpS0.31

BVpS2.76

TBVpS2.57

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	3.52%
ROE	3.86%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	34.93%
GM	21.42%
FCFM	4.84%

ROA(3y)-5.62%

ROA(5y)-9.8%

ROE(3y)-5.87%

ROE(5y)-10.3%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5Y-62.81%

GM growth 3YN/A

GM growth 5YN/A

F-Score6

Asset Turnover0.1

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	0
Debt/EBITDA	N/A
Cap/Depr	140.9%
Cap/Sales	11.18%
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	13.85%
Current Ratio	18.84
Quick Ratio	18.17
Altman-Z	5.53

F-Score6

WACC8.35%

ROIC/WACCN/A

Cap/Depr(3y)70.04%

Cap/Depr(5y)158.35%

Cap/Sales(3y)6.62%

Cap/Sales(5y)22.42%

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)190.91%

EPS 3YN/A

EPS 5Y-50.78%

EPS Q2Q%320%

EPS Next Y-144.2%

EPS Next 2Y-9.67%

EPS Next 3Y-39.52%

EPS Next 5Y-21.14%

Revenue 1Y (TTM)33.82%

Revenue growth 3Y16.47%

Revenue growth 5Y37.71%

Sales Q2Q%26.7%

Revenue Next Year18.44%

Revenue Next 2Y12.81%

Revenue Next 3Y7.09%

Revenue Next 5Y1.87%

EBIT growth 1Y26.61%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year90.36%

EBIT Next 3Y27.54%

EBIT Next 5Y9.95%

FCF growth 1Y112.55%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y143.99%

OCF growth 3YN/A

OCF growth 5YN/A

CRONOS GROUP INC (CRON) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens